Vol 10, Supp. C (2014)
Case report
Published online: 2014-08-29
The treatment of patients with metastatic prostate cancer with performance status equal 2 according to the Eastern Cooperative Oncology Group with the use of abiraterone — case reports
Abstract
Currently, metastatic prostate cancer should be considered as a chronic disease. Recent years have brought new opportunities in treatment of patients in the phase of the disease that is resistant to hormone therapy. The paper presents a description of the treatment of a patients with metastatic prostate cancer, with performance status equal 2, according to the Eastern Cooperative Oncology Group, with the use of abiraterone. That is a good illustration of the possibilities of multi-stage therapy of patients with castrate resistant prostate cancer.
Keywords: castrate resistant prostate cancerdocetaxelabiraterone